● Recruiting

Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Condition: DLBCL - Diffuse Large B Cell Lymphoma · Sponsor: Incyte Biosciences Italy S.r.l

PhaseN/A

Planned participants200

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The PRO-MIND study is an Italian, multicenter, prospective observational cohort study to evaluate the effectiveness and the safety of tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy in patient with DLBCL.

This description comes directly from the study's public registry record.

Talk to the study team

Nicola Battaglia · + 39 3429513636 · NBattaglia@incyte.com

Mario Lapecorella · MLapecorella@incyte.com

Always discuss trial participation with your own doctor first.

Locations (1)

Incyte Biosciences Italy S.r.l

Milan, Italy

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06299553